ICB with monoclonal antibodies targeting T‐cell inhibitory molecules such as PD‐1, PD‐L1 and CTLA‐4 has recently emerged as a novel treatment strategy with unprecedented survival benefits for cancer patients, especially for MSI‐H CRC patients. Here, CTLA4 is linked to colorectal carcinoma.